NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

Researchers from National University Hospital (NUH), National Cancer Institute, Singapore (NCIS), the Yong Loo Lin School of Medicine, National University of Singapore, Duke-NUS Medical School and ...

A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer.

A new targeted ovarian cancer treatment is helping women with hard-to-treat disease live longer, feel better, and gain ...

Peritoneal cancer is difficult to treat and has a poor survival prognosis. But a new and effective nanomedicine delivery system is offering some hope. The company is called NaDeNo and is well underway ...

Please provide your email address to receive an email when new articles are posted on . The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients ...

Veteran actor-politician Nafisa Ali Sodhi, 68, is battling stage 4 peritoneal cancer after previously overcoming stage 3 ...